#VisualAbstract: Golimumab effective at preserving insulin production in type 1 diabetes
1. In this randomized, double-blind, phase two trial, the use of golimumab led to more C-peptide production, indicative of improved ...
1. In this randomized, double-blind, phase two trial, the use of golimumab led to more C-peptide production, indicative of improved ...
1. In this randomized, double-blind, phase two trial, the use of golimumab led to more C-peptide production, indicative of improved ...
1. The closed-loop system maintained glucose levels within the target range for a significantly greater percentage of time for children ...
1. Insulin costs steadily increased from 2006-2017. However, the out-of-pocket costs to privately insured patients remained consistent, in-part due to ...
1. In this randomized noninferiority trial involving newborns with asymptomatic moderate hypoglycemia, initiation of treatment at a lower blood glucose ...
1. In this randomized controlled trial, patients with type 1 diabetes who used a closed-loop system spent a greater percentage ...
1. In this large, longitudinal cohort study from the United States, patients with poor health status were more likely to ...
1. In this descriptive case series, 55 cases of patients with diabetes who developed Fournier gangrene while using sodium-glucose cotransporter-2 ...
Better treatments are needed for diabetic retinopathy (DR), a microvascular complication of diabetes. Intensive glycemic treatment can delay DR onset ...
Multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) are two forms of intensive insulin regimens utilized by patients ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.